Evaluation of the inhibition performance of pyrrole derivatives against CYP450 isoforms
Authors/Creators
- 1. Medical University - Sofia, Sofia, Bulgaria
- 2. Government College University Faisalabad, Faisalabad, Pakistan
Description
Cytochrome P450 is a heme-containing superfamily accountable for the oxidation of various pharmacologically active drugs. The aim of this study was to conduct in silico and in vitro activity assessments of recently synthesized pyrrole-based compounds against three major CYP450 isoforms – CYP1A2, CYP2D6 and CYP3A4. The in vitro study contained specific cytochrome P450 isoform inhibitors and substrates (for CYP1A2, CYP2D6, and CYP3A4) to determine the inhibition performance of the tile compounds at 1 µM concentration. The in vitro data showed that none of the implemented molecules (MI_a-e and MII_a-e) are capable of inhibiting neither of the CYP isoforms. In addition, the potential interactions of the title compounds and the evaluated CYP isoforms were displayed after molecular docking with Glide (Schrödinger). Induced-fit simulations and binding free energy (MM/GBSA) calculations were applied to elucidate the accessibility in each CYP isoform. None of the pyrrole-based compounds exerted significant inhibition towards the applied isoenzymes. Two of the best scored compounds were visualized in the active site of CYP3A4 (PDB: 2V0M). Overall, good correlation between the in vitro results and the free binding MM/GBSA recalculations was observed.
Files
PHAR_article_122067.pdf
Files
(1.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:893d6c3cefe58896727cf64c022a4621
|
1.7 MB | Preview Download |
|
md5:9c11405d21a4bf70e3135502a127a627
|
49.3 kB | Preview Download |
Additional details
References
- Angelov B, Mateev E, Georgieva M, Tzankova V, Kondeva-Burdina M (2022) In vitro effects and in silico analysis of newly synthetized pyrrole derivatives on the activity of different isoforms of Cytochrome P450: CYP1A2, CYP2D6 and CYP3A4. Pharmacia 69(4): 1013–1017. https://doi.org/10.3897/pharmacia.69.e96626
- Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V (2020) Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics 12(9): 846. https://doi.org/10.3390/pharmaceutics12090846
- Iliev I, Georgieva S, Sotirova Y, Andonova V (2023) In silico study of the toxicity of hyperforin and its metabolites. Pharmacia 70(3): 435–447. https://doi.org/10.3897/pharmacia.70.e107041
- Kondeva-Burdina M, Mateev E, Angelov B, Tzankova V, Georgieva M (2022) In Silico Evaluation and In Vitro Determination of Neuroprotective and MAO-B Inhibitory Effects of Pyrrole-Based Hydrazones: A Therapeutic Approach to Parkinson's Disease. Molecules 27(23): 8485. https://doi.org/10.3390/molecules27238485
- Li Petri G, Spanò V, Spatola R, Holl R, Raimondi MV, Barraja P, Montalbano A (2020) Bioactive pyrrole-based compounds with target selectivity. European Journal of Medicinal Chemistry 208: 112783. https://doi.org/10.1016/j.ejmech.2020.112783
- Manikandan P, Nagini S (2018) Cytochrome P450 Structure, Function and Clinical Significance: A Review. Curr Drug Targets 19(1): 38–54. https://doi.org/10.2174/1389450118666170125144557
- Mateev E, Balaknska-Mitkova A, Peikova L, Dimitrova M, Kondeva-Burdina M (2022) In vitro and in silico inhibition performance of choline against CYP1A2, CYP2D6 and CYP3A4. Biotechnology & Biotechnological Equipment 36: 925–932. https://doi.org/10.1080/13102818.2022.2144452
- McDonnell AM, Dang CH (2013) Basic review of the cytochrome p450 system. Journal of the Advanced Practitioner in Oncology 4(4): 263–268. https://doi.org/10.6004/jadpro.2013.4.4.7
- Moroi K, Sato T (1975) Comparison between procaine and isocarboxazid metabolism in vitro by a liver microsomal amidase-esterase. Biochem Pharmacol 24(16): 1517–1521. https://doi.org/10.1016/0006-2952(75)90029-5
- Nelson SD, Mitchell JR, Snodgrass WR, Timbrell JA (1978) Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. JJournal of Pharmacology and Experimental Therapeutics 206(3): 574–585.
- Ogu CC, Maxa JL (2000) Drug interactions due to cytochrome P450. Proceedings: Baylor University Medical Center 13(4): 421–423. https://doi.org/10.1080/08998280.2000.11927719
- Tzankova D, Kuteva H, Mateev E, Stefanova D, Dzhemadan A, Yordanov Y, Mateeva A, Tzankova V, Kondeva-Burdina M, Zlatkov A, Georgieva M (2023) Synthesis, DFT Study, and In Vitro Evaluation of Antioxidant Properties and Cytotoxic and Cytoprotective Effects of New Hydrazones on SH-SY5Y Neuroblastoma Cell Lines. Pharmaceuticals (Basel) 16(9): 1198. https://doi.org/10.3390/ph16091198